American Journal of Kidney Diseases
Volume 51, Issue 4 , Pages 613-623 , April 2008

Expression of ACE and ACE2 in Individuals With Diabetic Kidney Disease and Healthy Controls

  • Sonoo Mizuiri, MD

      Affiliations

    • Department of Nephrology, Toho University School of Medicine, Tokyo, Japan
    • Corresponding Author InformationAddress correspondence to Sonoo Mizuiri, MD, Department of Nephrology, Toho University School of Medicine, 6-11-1 Omori-Nishi, Ohta-ku, Tokyo, 143-8541, Japan.
    • ,
  • Hiromichi Hemmi, PhD

      Affiliations

    • Department of Molecular Biology, Toho University School of Medicine, Tokyo, Japan
    • ,
  • Michitsune Arita, PhD

      Affiliations

    • Department of Molecular Biology, Toho University School of Medicine, Tokyo, Japan
    • ,
  • Yasushi Ohashi, MD

      Affiliations

    • Department of Nephrology, Toho University School of Medicine, Tokyo, Japan
    • ,
  • Yoshihide Tanaka, MD

      Affiliations

    • Department of Nephrology, Toho University School of Medicine, Tokyo, Japan
    • ,
  • Moriatsu Miyagi, MD

      Affiliations

    • Department of Nephrology, Toho University School of Medicine, Tokyo, Japan
    • ,
  • Ken Sakai, MD

      Affiliations

    • Department of Nephrology, Toho University School of Medicine, Tokyo, Japan
    • ,
  • Yukio Ishikawa, MD

      Affiliations

    • Department of Pathology, Toho University School of Medicine, Tokyo, Japan
    • ,
  • Kazutoshi Shibuya, MD

      Affiliations

    • Department of Surgical Pathology, Toho University School of Medicine, Tokyo, Japan
    • ,
  • Hiroki Hase, MD

      Affiliations

    • Division of Nephrology of Ohashi Hospital, Toho University School of Medicine, Tokyo, Japan.
    • ,
  • Atsushi Aikawa, MD

      Affiliations

    • Department of Nephrology, Toho University School of Medicine, Tokyo, Japan

Received 13 May 2007 ,Accepted 19 November 2007.

References 

  1. Carey RM, Siragy HM. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab. 2003;14:274–281
  2. Yoo TH, Li JJ, Kim JJ, et al. Activation of the renin-angiotensin system within podocytes in diabetes. Kidney Int. 2007;7:1019–1027
  3. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87:E1–E9
  4. Tipnis SR, Hooper NM, Hyde R, et al. A human homolog of angiotensin-converting enzyme: Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275:33238–33243
  5. Burns KD. The emerging role of angiotensin-converting enzyme-2 in the kidney. Curr Opin Nephrol Hypertens. 2007;16:116–121
  6. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: Functional, immunohistochemical, and molecular biological correlations. Am J Physiol. 1993;265:F477–F486
  7. Mizuiri S, Yoshikawa H, Tanegashima M, et al. Renal ACE immunohistochemical localization in NIDDM patients with nephropathy. Am J Kidney Dis. 1998;31:301–307
  8. Ye M, Wysocki J, William J, et al. Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: Implications for albuminuria in diabetes. J Am Soc Nephrol. 2006;17:3067–3075
  9. Mezzano S, Droguett A, Burgos ME, et al. Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int Suppl. 2003;86:S64–S70
  10. Tikellis C, Johnston CI, Forbes JM, et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension. 2003;41:392–397
  11. Ye M, Wysocki J, Naaz P, et al. Increased ACE2 and decreased ACE protein in renal tubules from diabetic mice (A renoprotective combination?). Hypertension. 2004;43:1120–1125
  12. Lely AT, Hamming I, van Goor H, et al. Renal ACE2 expression in human kidney disease. J Pathol. 2004;204:587–593
  13. Konoshita T, Wakahara S, Mizuno S, et al. Tissue gene expression of renin-angiotensin system in human type 2 diabetic nephropathy. Diabetes Care. 2006;29:848–852
  14. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183–1197
  15. Suzuki D, Miyazaki M, Jinde K, et al. In situ hybridization studies of matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and type IV collagen in diabetic nephropathy. Kidney Int. 1997;52:111–119
  16. Gellman DD, Pirani CL, Soothill JF, et al. Diabetic nephropathy: A clinical and pathologic study based on renal biopsies. Medicine (Baltimore). 1959;38:321–367
  17. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic colour fundus photographs—An extension of the modified Airlie House classification (ETDRS Report No 10). Ophthalmology. 1991;98:86–806
  18. Miyazaki M, Kubo M, Kiyohara Y, et al. Comparison of diagnostic methods for diabetes mellitus based on prevalence of retinopathy in a Japanese population: The Hisayama Study. Diabetologia. 2004;47:1411–1415
  19. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation (Modification of Diet in Renal Disease Study Group). Ann Intern Med. 1999;130:461–470
  20. Imai E, Horio M, Nitta K, et al. Estimation of glomerular filtration rate by the MDRD Study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol. 2007;11:41–50
  21. Miyake-Ogawa C, Miyazaki M, Abe K, et al. Tissue-specific expression of renin-angiotensin system components in IgA nephropathy. Am J Nephrol. 2005;25:1–12
  22. He L, Ding Y, Zhang Q, et al. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: Relation to the acute lung injury and pathogenesis of SARS. J Pathol. 2006;210:288–297
  23. Wysocki J, Ye M, Soler MJ, et al. ACE and ACE2 activity in diabetic mice. Diabetes. 2006;55:2132–2139
  24. Wong DW, Qudit GY, Reich H, et al. Loss of angiotensin-converting enzyme-2 (ACE2) accelerates diabetic kidney injury. Am J Pathol. 2007;171:438–451
  25. Soler MJ, Wysocki J, Ye M, et al. ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int. 2007;72:614–623
  26. Burrell LM, Johnston CI, Tikellis C, et al. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol. 2004;15:166–169
  27. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol. 2005;289:H2281–H2290
  28. Chapple MC, Ferrario CM. ACE and ACE2: Their role to balance the expression of angiotensin II and angiotensin-(1-7). Kidney Int. 2006;70:8–10
  29. Ingelfinger JR. ACE2: A new target for prevention of diabetic nephropathy. J Am Soc Nephrol. 2006;17:2957–2959
  30. Wakahara S, Konoshita T, Mizuno S, et al. Synergistic expression of ACE and ACE2 in human renal tissue and confounding effects of hypertension on the ACE/ACE2 ratio. Endocrinology. 2007;148:2453–2457
  31. Wolf G, Chen S, Ziyadeh FN. Perspectives in diabetes (From the periphery of the glomerular capillary wall toward the center of disease: Podocyte injury comes of age in diabetic nephropathy). Diabetes. 2005;54:1626–1634
  32. Forbes JM, Cooper ME, Oldfield MD, et al. Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol. 2003;14(suppl 3):S254–S258
  33. Thomas MC, Tikellis C, Burns WM, et al. Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol. 2005;16:2976–2984
  34. Vidotti DB, Casarini DE, Cristovam PC, et al. High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am J Physiol Renal Physiol. 2004;286:F1039–F1045
  35. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822–828
  36. Hamming I, Cooper ME, Haagmans BL, et al. The emerging role of ACE2 in physiology and disease. J Pathol. 2007;212:1–11
  37. Takase O, Marumo T, Imai N, et al. NF-κB-dependent increase in intrarenal angiotensin II induced by proteinuria. Kidney Int. 2005;68:464–473
  38. Oudit GY, Herzenberg AM, Kassiri Z, et al. Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol. 2006;168:1808–1820
  39. Kaplan NM. Phamacologic therapy. In:  Brady HR,  Wilcox CS editor. Therapy in Nephrology and Hypertension. Philadelphia, PA: Saunders; 1999;p. 397–403
  40. Jerez S, Peral de Bruno M, Coviello A. Cross talk between angiotensin II and alpha 1 adrenergic receptors in rabbit aorta: Role of endothelium. Pharmacology. 2004;43:402–409
  41. Bauer JH, Sunderrajan S, Reams G. Effects of calcium entry blockers on renin-angiotensin-aldosterone system, renal function and hemodynamics, salt and water excretion and body fluid composition. Am J Cardiol. 1985;56:62H–67H
  42. Mackie FE, Meyer TW, Campbell DJ. Effects of antihypertensive therapy on intrarenal angiotensin and bradykinin levels in experimental renal insufficiency. Kidney Int. 2002;61:555–5563
  43. Nakamura T, Saito Y, Saito T, et al. Azelnidipine down-regulates renal angiotensin-converting enzyme and mineralocorticoid receptor mRNA in diabetic hypertensive rats. J Pharmacol Sci. 2006;102:239–242

 Originally published online as doi:10.1053/j.ajkd.2007.11.022 on February 18, 2008.

PII: S0272-6386(07)01608-3

doi: 10.1053/j.ajkd.2007.11.022

American Journal of Kidney Diseases
Volume 51, Issue 4 , Pages 613-623 , April 2008

Article Tools

* Image Usage & Resolution